We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

First One-Hour, Direct-from-Blood Sepsis Test Receives FDA Clearance

By LabMedica International staff writers
Posted on 01 Dec 2021
Print article
Image: SeptiCyte RAPID test (Photo courtesy of Immunexpress, Inc.)
Image: SeptiCyte RAPID test (Photo courtesy of Immunexpress, Inc.)

A fully automated diagnostic tool quantifies the relative expression levels of genes involved in a patient's immune response to infection to aid in a diagnosis in one hour for patients suspected of sepsis.

Immunexpress, Inc. (Seattle, WA, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SeptiCyte RAPID test as an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.

The increasing incidence of sepsis, which has accelerated with the COVID 19 pandemic, is well recognized and has been generally attributed to the growing prevalence of chronic conditions in aging populations. The clinical presentation of sepsis is often hard to identify early; fever is not always present, and it can often go unrecognized clinically for extended periods. Sepsis remains a leading cause of morbidity and mortality among intensive care unit (ICU) patients. For each hour that treatment initiation is delayed after diagnosis, sepsis-related mortality increases by approximately 8%. Therefore, maximizing effective care requires early recognition and initiation of treatment protocols.

SeptiCyte RAPID is the first FDA cleared test to differentiate sepsis from non-infectious systemic inflammation to aid in a sepsis diagnosis within approximately one hour for patients suspected of sepsis. SeptiCyte RAPID contains all the reagents needed for quantification of gene expression using a reverse transcription polymerase chain reaction (PCR) to determine the relative expression levels of host response genes directly from whole blood. The process is fully automated in a user-friendly, hands-free format, and a result is obtained in one hour.

"SeptiCyte RAPID has the potential to transform sepsis diagnosis, addressing a critically unmet need in the ICU," said Roy Davis, M.D., Ph.D., Chief Medical Officer of Immunexpress. "SeptiCyte RAPID has been evaluated in hospitals since 2019. Major hospital systems with which we have worked are anxiously waiting to incorporate this into the current diagnostic tool set, allowing clinicians to make swift and accurate clinical decisions, ultimately improving patient outcomes."

"It has been a long journey to transfer our clinically proven novel biomarker technology from our eight hour FDA-cleared SeptiCyte LAB product in 2017, to the advanced one hour sample-to-answer Biocartis Idylla testing platform," added Rollie Carlson, Ph.D., Chief Executive Officer of Immunexpress. "This FDA clearance could not have been achieved without the dedication of the Immunexpress team, the support of our investors, and our clinical partners around the globe."

Related Links:
Immunexpress, Inc. 

Gold Supplier
Nucleic Acid Extraction System
Tube Handler
BioMicroLab XL20
POC Clinical Chemistry Analyzer
Integrated Urinalysis Chemistry Analyzer

Print article
IIR Middle East



view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.